Avastin has struck out at NICE again. The U.K. cost-effectiveness watchdog says it's not inclined to back the blockbuster Roche ($RHHBY) drug as a treatment for ovarian cancer. At about $4,000 per month, NICE said, Avastin simply doesn't deliver enough value for the money.
One of the reasons counterfeit Avastin made its way into the U.S. this year was because physician clinics, looking to boost their earnings, were willing to buy drugs whose origins should have been suspect. And the FDA is not going to just let all of them off the hook.
At least some of the cancer drugs that have surfaced as part of an investigation into counterfeit Avastin were legitimate cancer drugs made by Roche but in a plant not overseen by the FDA.
Regeneron ($REGN) is eyeing a big expansion at an upstate New York plant now that its macular degeneration drug has taken off. The company plans to spend $70 million on new buildings and upgrades--and add 300 jobs--at the Albany-area facility.
While other drugmakers cut prices, set up access plans or wrangle with the Chinese government to sell products in that country, Roche ($RHHBY) is taking a more indirect tack. As Bloomberg reports, the Swiss drugmaker has teamed up with the reinsurer Swiss Re to sell private insurance to middle-class Chinese. That way, more patients can afford to use the company's pricey cancer drugs.
Roche's blockbuster Avastin, already approved for any number of cancer treatments, has gotten a new indication in the European Union.
Oncologists say they're more-or-less ready to start using biosimilar versions of easier-to-mimic therapies such as erythropoiesis-stimulating agents (ESAs), which treat anemia in cancer and kidney patients.
Levels of protein in the blood could predict which advanced bowel cancer patients will respond to Genentech/Roche's Avastin, a monoclonal antibody that increases survival in 10% to 15% of patients with the disease.
Did Roche ($RHHBY) bungle tens of thousands of adverse-event reports? European regulators aim to find out. The European Medicines Agency says it has started an "infringement procedure" against the Swiss drugmaker, to probe allegations that it dragged its feet on reporting potential side effects.
Watch out, oncology drugmakers. Memorial Sloan-Kettering Cancer Center has made a move that could crimp your ambitions for premium pricing. The leading hospital says it will exclude Sanofi's ($SNY) new colorectal cancer drug Zaltrap from its treament protocols--because its price is twice as high as competing treatments, but has proven no more effective than its rivals, namely Roche's ($RHHBY) Avastin.